GLP1-receptor agonists landscape: manufacturer mapping and regulatory pathways
17 September 2026
| Report
Overview
This report presents a global mapping of glucagon-like peptide-1 receptor agonist manufacturers, with a particular focus on semaglutide. The mapping describes manufacturers, manufacturing type and marketing authorization holders and examines the patent landscape and regulatory requirements for semaglutide. The report highlights substantial differences in regulatory approaches across countries and outlines proposed actions to support regulatory harmonization.
WHO Team
Global Diabetes Compact,
Noncommunicable Diseases and Mental Health (NMH)
Editors
World Health Organization
Number of pages
31
Reference numbers
ISBN: 978-92-4-012514-8
Copyright
